Plant Variety Rights

(PVRs)

Experts in IP Protection for Plant Variety Inventions


Improvement of crop and ornamental species by genetic modification or modern breeding techniques remains a significant area of innovation. A number of IP rights may be suitable for protecting plant inventions, including patents, trade marks, plant Variety Rights (PVRs) and entry on the national list or common catalogue. Our experienced IP specialists are well placed to assist our clients in this area, having a wealth of practical experience.

In Europe, individual plant varieties that are distinct, uniform and stable can be protected either nationally or at European Community level. Separately, European and national patents can be obtained for plants and plant-related inventions which are not restricted to plant varieties per se, although certain plant breeding methods and plants obtained by those methods are excluded from patentability.  Despite the EU’s strict policies on growing genetically modified crops and uncertainty surrounding the use of genetic resources in plant breeding, there is considerable commercial interest in these technical areas and in IP protection for the output of biotech research and classical breeding programs.

Our expert IP team is led by Frances Salisbury, who has a PhD in plant molecular genetics. An expert in this field Frances has completed the official World Intellectual Property Organisation (WIPO) course on Plant Variety Protection under the UPOV Convention.

Read our Plant Variety Rights Law and Practice guide.

Read our blogs

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

by Helen Brew Gerlach

We are delighted to release our latest report Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know. View the report here.

Discontinuous Epitope Claims get Green Light in Europe

Discontinuous Epitope Claims get Green Light in Europe

by Edward Couchman

Patents for antibodies defined by discontinuous epitopes have garnered a lot of attention recently. Following the decision of the US Supreme Court in Amgen v Sanofi, it has now been the turn of the ...

Hummingbird Bioscience’s multi-payload ADC technology licensed by Callio Therapeutics

Hummingbird Bioscience’s multi-payload ADC technology licensed by Callio Therapeutics

by Adam Gregory

We are delighted to congratulate our client Hummingbird Bioscience on the successful out-licensing of multi-payload antibody-drug conjugate (ADC) technology and related intellectual property and ...

UK's Alternative Protein Sector Takes Major Leap with Landmark Collaboration

UK's Alternative Protein Sector Takes Major Leap with Landmark Collaboration

by Nick Sutcliffe

In a landmark move for the UK's alternative protein sector, four leading research centres - the Bezos Centre for Sustainable Protein (BCSP), the Microbial Food Hub, the Cellular Agriculture ...

Oncolytic Virotherapy (OVT) – A Technology Finally Coming of Age?

Oncolytic Virotherapy (OVT) – A Technology Finally Coming of Age?

by Nick Sutcliffe

The potential of viruses to selectively infect and kill cancer cells was first recognised over a century ago. However, translating this potential into effective cancer treatments has proven to be ...

How AI is Shaping the Future of MedTech - a new special report

How AI is Shaping the Future of MedTech - a new special report

by Joanna Smith

We are delighted to release our latest report How AI is Shaping the Future of MedTech. View the report here.

Forward Magazines 4

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.